1.. Resource utility {#S1}
====================

MAP2 is a widely-used marker for mature neurons. This HUES66 hESC line with doxycycline-inducible *NEUROG2* and *NEUROG1* and a MAP2-tdTomato knock-in expresses a red fluorescent protein upon neuronal differentiation. This cell line can help identify critical factors in neuronal differentiation or to study how newly-formed neurons integrate into neural networks *in vivo.*

2.. Resource details {#S2}
====================

We generated a HUES66 human embryonic stem cell (hESC) line with inducible expression of *NEUROG2/1* via lentiviral transgenesis and a knock-in MAP2-T2A-tdTomato fluorescent reporter via CRISPR-mediated homologous recombination (HR). As previously described ([@R1]; [@R2]), doxycycline-inducible expression of *NEUROG2/1* was achieved via lentiviral delivery of transgenes for the reverse tetracycline transactivator 3 (rtTA3) linked to the blasticidin resistance gene and tet-inducible expression of the master neuronal transcription factors *NEUROG2* and *NEUROG1* linked to the puromycin resistance gene.

To create the neuron reporter line, we targeted the beginning of the 3′ untranslated region (UTR) of the *MAP2* gene by designing a Cas9 single-guide RNA that cuts 31 bp after the MAP2 stop codon ([Fig. 1A](#F1){ref-type="fig"}). We combined the Cas9 plasmid with a donor vector containing \~850 bp homology arms (HA) flanking the *MAP2* stop codon ([Fig. 1B](#F1){ref-type="fig"}). The donor vector contains a self-cleaving 2A peptide and tdTomato fluorescent protein that are in frame with the end of MAP2. The donor also contains a zeocin selection cassette flanked by FRT sites to enable selection after successful integration and a small mutation in the right HA at the Cas9 protospacer-adjacent motif (PAM) to prevent Cas9 from cutting either the donor vector or the genome after HR. After integration of the donor, transient expression of *Flp* recombinase removes the zeocin selection cassette ([Fig. 1C](#F1){ref-type="fig"}).

We transfected HUES66 with inducible expression of *NEUROG2/1*, a plasmid containing Cas9 nuclease and the sgRNA and a plasmid with the donor template ([Fig. 1D](#F1){ref-type="fig"}). Two days after transfection, zeocin was used to select for cells that underwent successful HR at the *MAP2* locus. Zeocin selection was maintained for 5 days to select for cells with stable integration. Using dilution plating, we established monoclonal lines and validated successful HR by PCR amplification with a primer outside the HA and a primer that only binds the *tdTomato* transgene. After initial validation, we excised the bleomycin resistance cassette by transient transfection of *Flp* recombinase. We performed a second dilution plating and verified excision using PCR. In total, the HUES66 cells were passaged 14 times over the course of the derivation of the monoclonal reporter line.

The selected monoclonal line (NYGCe001-A) contains the desired in-frame knock-in fragment and a designed GG to TT mutation at the PAM sequence (to prevent re-cutting by Cas9) ([Tables 1](#T2){ref-type="table"} and [2](#T3){ref-type="table"}). On the other allele, there is a small deletion in a noncoding region near the cut site (3′ UTR) ([Fig. 1E](#F1){ref-type="fig"}). Using low-pass, whole-genome sequencing (WGS) of parental and knock-in lines, we confirmed that NYGCe001-A had no copy number changes at ≤5 Mb resolution. To evaluate the pluripotency and differentiation ability of the selected line, we performed immunocytochemical staining of the pluripotency marker OCT3/4 and the neuron marker MAP2 ([Fig. 1F](#F1){ref-type="fig"}). Prior to differentiation, all NYGCe001-A cells examined were positive for OCT3/4 and negative for MAP2 by immunofluorescence and, using flow cytometry, we found that 99.3% cells were positive for the pluripotency cell surface marker TRA-1--81 by flow cytometry ([Supplemental Fig. 1A](#SD1){ref-type="supplementary-material"}). Also, using chemical growth factors, we confirmed that NYGCe001-A hESCs could differentiate into all three germ layers via immunofluorescent staining for layer-specific marker genes ([Supplemental Fig. 1B](#SD1){ref-type="supplementary-material"}).

After 5 days of doxycycline-induced (*NEUROG2/1*-driven) neural differentiation, all cells examined stained negative for OCT3/4 and positive for MAP2 by immunofluorescence. Similarly, the endogenous tdTomato fluorescence signal for the selected line was negative prior to doxycycline induction, but, after doxycycline treatment, tdTomato expression was initially visible at day 5 and intensified at day 10 ([Fig. 1G](#F1){ref-type="fig"}). Flow cytometry at day 7 post-doxycycline induction indicated that 99.2% of cells were tdTomato positive ([Fig. 1H](#F1){ref-type="fig"}).

3.. Materials and methods {#S3}
=========================

3.1.. Cell culture {#S4}
------------------

HUES66 human embryonic stem cells (hESCs) were maintained according to the Enhanced Culture Platform, which is less prone to spontaneous differentiation and aids in culturing hESCs as single cells for selection after genome engineering ([@R2]; [@R3]; [@R5]). Briefly, hESCs were maintained in Essential 8 media (ThermoFisher) supplemented with 100 μg/mL Normocin (InvivoGen) and cultured in standard tissue culture dishes coated with Geltrex (ThermoFisher) at 37 °C in 5% CO~2~. For passaging, the cells were dissociated using Accutase (STEMCELL). When subculturing or growing at very low density, we added 10 μM Rho kinase inhibitor Y-27632 (MilliporeSigma) to the culture medium to increase survival.

3.2.. Lentiviral transduction {#S5}
-----------------------------

Lentiviral delivery was used to introduce constitutive expression of reverse tetracycline transactivator (rtTA3) driven by the human elongation factor-1a promoter (hEF1a) and inducible expression of *NEUROG2/1* driven by a tetracycline response element promoter into hESCs. Lentivirus was produced as previously described ([@R4]). The two viral constructs were packaged separately and then pooled at the time of transduction.

3.3.. Transfection {#S6}
------------------

We cloned a single guide RNA (sgRNA) targeting the 3′ end of the *MAP2* gene into lentiCRISPRv2 (Addgene 52961), a plasmid that contains both Cas9 and a sgRNA cassette, as previously described ([@R4]). We transfected hESCs using Lipofectamine 3000 (ThermoFisher) with this CRISPR construct and a plasmid donor template T2A-tdTomato-FRT-SV40 promoter-Zeo-SV40pA-FRT flanked by 837 bp left and 876 bp right homology arms. We plated 0.4 million cells per well into a 12-well dish 6 h before transfection. A total of 2 μg plasmid was transfected into the plated cells with 2 μl of Lipofectamine 3000. Culture media was fully refreshed 12 h after transfection. After successful homology-directed integration of the donor, we removed the zeocin selection cassette using recombinase plasmid pCAG-Flpe (Addgene 13787).

3.4.. In vitro differentiation assay {#S7}
------------------------------------

NYGCe001-A cells were differentiated to ectoderm, mesoderm, and endoderm using the media supplements and growth factors in the Human Pluripotent Stem Cell Functional Identification Kit (R&D Systems SC027B). To validate lineage commitment, differentiated cells were stained with anti-Otx2 (ectoderm), anti-Brachyury (mesoderm), and anti-SOX17 (endoderm).

3.5.. Immunocytochemistry {#S8}
-------------------------

Cells were grown on Geltrex-coated coverslips and fixed with 4% paraformaldehyde and 4% sucrose in PBS at room temperature for 5 min followed by washing 3 times with PBS. The fixed cells were then permeabilized with 0.1% Triton X-100 in PBS for 5 min, washed 3 times with PBS, and incubated in 3% bovine serum albumin in PBS for 1 h to block nonspecific binding. The cells were incubated overnight with the primary antibodies at 4 °C overnight followed by incubation with the secondary antibodies at room temperature for 1 h. The images were collected using an Axio Observer Z1 microscope (Zeiss).

3.6.. Flow cytometry {#S9}
--------------------

The cells were dissociated into a single cell suspension using Accutase and passed through a 35 μm cell strainer (BD Falcon). Flow cytometry data was acquired on a Sony SH800 and analyzed using FlowJo v10.5 (BD).

3.7.. Karyotype analysis {#S10}
------------------------

Karyotyping was done using the digital karyotyping service from FIND Genomics. Briefly, DNA was extracted using the GeneJET DNA Purification Kit (ThermoFisher), followed by nanopore library preparation using the Rapid Barcoding Kit (Oxford Nanopore). The gDNA library was sequencing using a MinION nanopore sequencer (Oxford Nanopore). The collected DNA data was analysed using the FIND Cell software (FIND Genomics) and analyzed to confirm cell population identity and digital karyotype with a structural variant detection resolution of 5Mb or greater. Digital karyotyping were done on 3 separate genomic DNA samples.

3.8.. Mycoplasma detection {#S11}
--------------------------

We verified the absence of mycoplasma in the culture medium using a luminescence-based assay, MycoAlert PLUS (Lonza).

3.9.. Short tandem repeat analysis {#S12}
----------------------------------

STR analysis was performed by ATCC using a PowerPlex 18D kit (Promega) and the Prism 3500xl Genetic Analyzer (Applied Biosystems). STR profiles were analyzed using GeneMapper ID-X v1.2 (Applied Biosystems).
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  Unique stem cell line identifier        NYGCe001-A
  --------------------------------------- ------------------------------------------------------------------------------------------------------------
  Alternative name(s) of stem cell line   HUES66-DoxNGN-MAP2-tdTomato
  Institution                             New York Genome Center
  Contact information of distributor      Neville Sanjana (<neville@sanjanalab.org>)
  Type of cell line                       hESC
  Origin                                  Human
  Additional origin info                  Sex: Female
  Cell Source                             Harvard Stem Cell Institute
  Clonality                               Monoclonal
  Method of reprogramming                 N/A
  Genetic Modification                    Yes
  Type of Modification                    Lentiviral transgenic for Dox-inducible *Neurogenin2/1* and CRISPR-Cas9 knock-in of tdTomato at MAP2 locus
  Associated disease                      N/A
  Gene/locus                              Chr2/MAP2
  Method of modification                  Lentiviral transgenic; CRISPR-Cas9 homology-mediated repair following by Flp recombinase
  Name of transgene or resistance         Transgenes: *NEUROG2, NEUROG1, rtTA3*, tdTomato; Resistance markers: blasticidin, puromycin
  Inducible/constitutive system           TET-ON (rtTA3) for *NEUROG2--2A-NEUROG1--2A-PuroR*
  Date archived/stock date                *N/A*
  Cell line repository/bank               *N/A*
  Ethical approval                        New York Genome Center IBC (ISCRO003-Y2-M0); HUES66 line from Harvard Stem Cell Institute

###### 

Characterization and validation.

  Classification              Test                                                Result                                                                                                                                                                                                              Data
  --------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  Morphology                  Photography                                         Normal                                                                                                                                                                                                              [Fig. 1G](#F1){ref-type="fig"}
  Phenotype                   Immunocytochemistry                                 100% of cells were stained positive for OCT3/4 before Dox induction. 100% of cells were stained positive for MAP2 at day 5 after Dox induction.                                                                     [Fig. 1F](#F1){ref-type="fig"}
                              Fluorescent photography                             All cells showed tdTomato signal at day 10 after Dox induction.                                                                                                                                                     [Fig. 1G](#F1){ref-type="fig"}
                              Flow cytometry                                      99.2% of NYGCe001-A cells were tdTomato positive at day 7 after Dox induction.                                                                                                                                      [Fig. 1H](#F1){ref-type="fig"}
                              Flow cytometry                                      99.3% of NYGCe001-A cells were stained positive for TRA-1--81.                                                                                                                                                      [Supplemental Fig. 1A](#SD1){ref-type="supplementary-material"}
  Genotype Identity           Digital karyotype                                   46XX : 2.5 -- 10 MB resolution                                                                                                                                                                                      [Supplemental Fig. 2](#SD2){ref-type="supplementary-material"}
                              Microsatellite PCR (mPCR)                           Not performed                                                                                                                                                                                                       
  Identity                    STR analysis                                        18 sites tested                                                                                                                                                                                                     Submitted in archive with journal
  Mutation analysis                                                                                                                                                                                                                                                                                   
                              Sequencing                                          Precise insertion in chr2 at desired location; small deletion on the other allele.                                                                                                                                  [Fig. 1E](#F1){ref-type="fig"}
  Mutation analysis           WGS                                                 N/A                                                                                                                                                                                                                 
  Microbiology and virology   Mycoplasma                                          Mycoplasma testing by luminescence: Negative.                                                                                                                                                                       [Supplemental Fig. 3](#SD3){ref-type="supplementary-material"}
  Differentiation potential   NEUROG2/1-overexpression to differentiate neurons   Expression of neuron marker MAP2.                                                                                                                                                                                   [Fig. 1F](#F1){ref-type="fig"}
                              *In vitro* differentiation assay                    Cells from ectoderm differentiation were stained positive for Otx2; cells from mesoderm differentiation were stained positive for Brachyury; cells from endoderm differentiation were stained positive for SOX17.   [Supplemental Fig. 1B](#SD1){ref-type="supplementary-material"}

###### 

Reagents details.

  Antibodies used for immunocytochemistry/flow-citometry                                                                                          
  -------------------------------------------------------- ---------------------------------------- --------------------------------------------- --------------------------------------------------------------
  Pluripotency Marker                                      Mouse anti-OCT3/4                        1:500                                         Santa Cruz Biotech Cat\# sc-5279,RRID: AB_628051
                                                           Mouse anti-TRA-1--81 (Podocalyxin), PE   1:20                                          ThermoFisher Cat\# 12--8883--80 RRID: AB_891608
  Differentiation Marker                                   Guinea pig anti-MAP2                     1:1000                                        Synaptic Systems Cat \# 188 004,RRID: AB_2138181
                                                           Goat anti-SOX17                          1:500                                         R&D Systems Cat\# AF1924, RRID: AB_355060
                                                           Goat anti-Otx2                           1:500                                         R&D Systems Cat\# AF1979, RRID: AB_2157172
                                                           Goat anti-Brachyury                      1:500                                         R&D Systems Cat\# BAF2085 RRID: AB_2303014
  Secondary antibodies                                     Donkey anti-guinea pig Alexa 647         1:1000                                        Jackson ImmunoResearch Cat\# 706--605--148, RRID: AB_2340476
                                                           Goat anti-mouse Alexa 488                1:1000                                        ThermoFisher Scientific Cat\# A32723, RRID: AB_2633275
                                                           Donkey anti-goat Northern Lights 557     1:200                                         R&D Systems Cat\# NL001, RRID: AB_663766
  Primers                                                                                                                                         
                                                           **Target**                               **Forward/Reverse primer (5′--3′)**           
  Targeted mutation analysis/sequencing                    MAP2 exon 15, tdTomato knock-in          aggtcccagattgtagacctgg/ cgtccatgccgtacaggaa   
  Targeted mutation analysis/sequencing                    tdTomato knock-in, MAP2 3′ UTR           tcggaatcgttttccgggac/ gccttcaggcacatgaaaggt   
